INS and Insulin resistance: Interestingly, treatment of these subjects with the insulin sensitizing drug rosiglitazone enhanced insulin sensitivity and reduced plasma concentration of ADMA, a correlation that remained significant even after adjusting for risk factors associated with insulin resistance.